Form 4: Amgen EVP David M. Reese Reports Acquisition of 12,407 Shares of Common Stock

David M. Reese, EVP & Chief Technology Officer of Amgen, reports acquiring 12,407 shares of common stock on March 6, 2024.

Summary

• On March 6, 2024, David M. Reese, the EVP & Chief Technology Officer of Amgen Inc., acquired 12,407 shares of Amgen's common stock.
• Following this transaction, Reese directly owns 66,653 shares of Amgen common stock.
• The acquired shares include restricted stock units (RSUs) that will vest on various dates in the future.
• These RSUs will be paid in shares of Amgen's common stock on a one-to-one basis.
• The shares also include dividend equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the acquisition of shares by a high-ranking executive often signals confidence in the company's prospects. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of shares by a high-ranking executive like the Chief Technology Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This filing indicates an acquisition of shares by a key executive, which is generally viewed positively by the market.

Stakeholder Impact

• The acquisition of shares by a key executive could positively influence shareholder sentiment.

Key Dates